Image

Global Hyperuricemia Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hyperuricemia Drugs Market, By Type (Asymptomatic Hyperuricemia, Symptomatic Hyperuricemia, Others), Diseases (Gout, Kidney Stone, Others), Drugs (Tropical Nonsteroidal Anti-Inflammatory Drugs, Xanthine Oxidase Inhibitors, Selective Uric Acid Reabsorption Inhibitor (SURI), Uricosuric Agents, Antigout Agents, Carbonic Anhydrase Inhibitors, Glucocorticoids, Urate Oxidase Enzyme (Recombinant), Alkalinizing Agent, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Hyperuricemia Drugs Market

Hyperuricemia Drugs Market Analysis and Size

The global hyperuricemia drugs market is expected to witness significant growth during the forecast period. As per the data published in National Institute on Alcohol Abuse and Alcoholism, U.S. an average of 17 million U.S. citizens suffered from alcohol use disorder in 2011. The life expectancy of people is increasing worldwide, that has led to a rise in the elderly population. This trend has led to a higher occurrence of this condition and per capita demand for its therapeutics, thus positively affecting their industry.

Data Bridge Market Research analyses a growth rate in the global hyperuricemia drugs market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hyperuricemia Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Asymptomatic Hyperuricemia, Symptomatic Hyperuricemia, Others), Diseases (Gout, Kidney Stone, Others), Drugs (Nonsteroidal Anti-Inflammatory Drugs, Xanthine Oxidase Inhibitors, Selective Uric Acid Reabsorption Inhibitor (SURI), Uricosuric Agents, Antigout Agents, Carbonic Anhydrase Inhibitors, Glucocorticoids, Urate Oxidase Enzyme (Recombinant), Alkalinizing Agent, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland)

Market Opportunities

  • Rising R&D and New Drug Approvals
  • Increasing Collaborations and Market Expansion

Market Definition

Hyperuricemia is the type of condition wherein an excessive level of uric acid is produced in the blood. The level of uric acid in the blood is the balance between the breakdown of purines and the rate of uric acid excretion. The alteration in the uric acid level may cause hyperuricemia. High uric acid can result in serious diseases such as painful arthritis called gout. Nearly 43.3 million Americans have hyperuricemia and gout conditions. 

Global Hyperuricemia Drugs Market Dynamics

Drivers

  • Availability of Advanced Treatment Procedures

With each decade, varied treatment methods are available to help the patients' faster recovery. Treatment advancements in terms of hearing aids, corrective lenses are on the rise. Thus, it acts as a major driver in the market growth.

  • Increasing Incidence in Elderly Population

Myelofibrosis cases are mostly witnessed in the age group ≤ 40 years, 41−60 years, and > 60 years. The >60 years group saw highest number of patients mostly around 10,275 in 2021 in the U.S. In 2021, eligible treatment population of myelofibrosis accounted for 9,511 cases in the U.S. Thus, this elderly population with higher chances of getting this disease boosts the market growth.

Opportunities

  • Rising R&D and New Drug Approvals

Numerous clinical trials are carried out by several research institutes and companies in order to discover most efficient drug for rearming the disorder. For instance, Ardea Biosciences, Inc. is conducting phase 2 clinical trials for testing the efficiency of RDEA806 for treatment of hyperuricemia. Hebei Medical University is conducting phase 3 trials to test the hypothesis that prednisone is superior over allopurinol in renal function improvement in heart failure patients with hyperuricemia. TWi Biotechnology, Inc. was awarded with U.S. patent in 2014 for AC – 201 which is effective in treating hyperuricemia.   

  • Increasing Collaborations and Market Expansion

Some of the bulging companies operating in the market insist on collaborations for development, broader product portfolios, and regional expansion in developing markets. These market players' major strategic undertakings to increase their market share. Thus, these factors are growing the market.

 Restraints/Challenges

  • Lack of Awareness

The lack of awareness about these disorders and the unavailability of numerous awareness programs hamper the market growth. The available drugs have not shown disease-modifying activity and are still mostly inadequate for managing major unmet needs.

  • High Cost

The huge expenditure associated with these agents hamper the market growth. The huge drug development and associated processes hamper the market's growth.

This global hyperuricemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hyperuricemia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hyperuricemia Drugs Market Scope

The global hyperuricemia drugs market is segmented on the basis of type, diseases, drugs, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Asymptomatic Hyperuricemia
  • Symptomatic Hyperuricemia
  • Others

Diseases

  • Gout
  • Kidney Stone
  • Others

Drugs

  • Nonsteroidal Anti-Inflammatory Drugs
  • Xanthine Oxidase Inhibitors
  • Selective Uric Acid Reabsorption Inhibitor (SURI)
  • Uricosuric Agents, Antigout Agents
  • Carbonic Anhydrase Inhibitors
  • Glucocorticoids, Urate Oxidase Enzyme (Recombinant)
  • Alkalinizing Agent
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

 Hyperuricemia Drugs Market Regional Analysis/Insights

The global hyperuricemia drugs market is analyzed and market size insights and trends are provided by type, diseases, drugs, distribution channel and end-user as referenced above.

The major countries covered in the global hyperuricemia drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for global hyperuricemia drugs market market throughout the forecasted period due to increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and presence of generic manufacturers.

North America dominates the market due to the advancement of technology for kidney diseases and increasing initiatives taken by the pharmaceutical organizations to generate novel formulation.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hyperuricemia Drugs Market Share Analysis

The global hyperuricemia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hyperuricemia drugs market.

Key players operating in the global hyperuricemia drugs market include:

  • Pfizer Inc (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Mylan N.V. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol Myers Squibb Company (U.S.)
  • GSK Plc. (U.K.)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd (India)
  • Dr. Reddy's Laboratories Ltd (India)
  • Endo International plc (Ireland)

 

 


SKU-
Why Choose Us


Frequently Asked Questions

The factors such as the availability of advanced treatment procedures and increasing incidence in the elderly population are acting as the major drivers for the global hyperuricemia drugs market.
The major companies involved in the Hyperuricemia Drugs Market report are Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland).
The Hyperuricemia Drugs Market report is segmented by Type, Diseases, Drugs, End-Users, and Distribution Channel
North America dominates the market due to the advancement of technology for kidney diseases and increasing initiatives taken by the pharmaceutical organizations to generate novel formulation.